Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Gliclazide | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Gliclazide | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Gliclazide | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Gliclazide | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Gliclazide | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | | Gliclazide | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Gliclazide | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | Gliclazide | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Gliclazide | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.24E-03 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | Gliclazide | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Gliclazide | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | Gliclazide | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Gliclazide | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Gliclazide | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | | Gliclazide | hsa03013 | RNA transport | 5.01E-03 | 12 | P52298, O14893, P61326, P38919, P37198, Q7Z3B4, P35658, Q14152, P55884, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, EIF4A3, NUP62, NUP54, NUP214, EIF3A, EIF3B, EIF3J, RPP38, TACC3 | More | | Gliclazide | hsa03020 | RNA polymerase | 3.25E-06 | 4 | P30876, P62487, Q9GZM3, P52435 | POLR2B, POLR2G, POLR2J2, POLR2J | More | | Gliclazide | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Gliclazide | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Gliclazide | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Gliclazide | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Gliclazide | hsa04062 | Chemokine signaling pathway | 9.23E-03 | 10 | P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | Gliclazide | hsa04064 | NF-kappa B signaling pathway | 9.70E-03 | 12 | O00463, P14778, P01584, P01375, Q04759, Q13077, Q16548, P06239, Q8WV28, P24522, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TNF, PRKCQ, TRAF1, BCL2A1, LCK, BLNK, GADD45A, CXCL1, CYLD | More | | Gliclazide | hsa04071 | Sphingolipid signaling pathway | 8.10E-04 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Gliclazide | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Gliclazide | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | | Gliclazide | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | | Gliclazide | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | | Gliclazide | hsa04217 | Necroptosis | 4.42E-04 | 6 | P07900, P15104, P05141, P01584, P0C0S5, Q13557 | HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D | More | | Gliclazide | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Gliclazide | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | Gliclazide | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Gliclazide | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Gliclazide | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Gliclazide | hsa04390 | Hippo signaling pathway | 4.35E-02 | 2 | P63261, O15105 | ACTG1, SMAD7 | More | | Gliclazide | hsa04530 | Tight junction | 4.35E-02 | 2 | P63261, Q92974 | ACTG1, ARHGEF2 | More | | Gliclazide | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Gliclazide | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Gliclazide | hsa04613 | Neutrophil extracellular trap formation | 4.70E-04 | 16 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q6FI13, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, H2AC18; H2AC19, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Gliclazide | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Gliclazide | hsa04625 | C-type lectin receptor signaling pathway | 8.11E-03 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Gliclazide | hsa04640 | Hematopoietic cell lineage | 4.31E-02 | 10 | P13612, P14778, P27930, P15144, P11836, P09693, P01732, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD3G, CD8A, HLA-DOB, TNF, IL1B | More | | Gliclazide | hsa04650 | Natural killer cell mediated cytotoxicity | 3.07E-04 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | | Gliclazide | hsa04657 | IL-17 signaling pathway | 2.73E-05 | 11 | P07900, O00463, Q16539, P49841, P09341, P19875, P14780, Q9UJX4, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, ANAPC5, LCN2, TNF, IL1B | More | | Gliclazide | hsa04658 | Th1 and Th2 cell differentiation | 1.26E-02 | 10 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765, P23458 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB, JAK1 | More | | Gliclazide | hsa04659 | Th17 cell differentiation | 7.88E-04 | 17 | Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P01584, P08238, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, IL1B, HSP90AB1, CD3E, CD3G, CD247, JAK1 | More | | Gliclazide | hsa04660 | T cell receptor signaling pathway | 1.11E-02 | 11 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Gliclazide | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Gliclazide | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Gliclazide | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Gliclazide | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.17E-02 | 8 | P14778, P01584, P51828, P22694, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2 | More | | Gliclazide | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | Gliclazide | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Gliclazide | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Gliclazide | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Gliclazide | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Gliclazide | hsa04932 | Non-alcoholic fatty liver disease | 9.70E-03 | 4 | P18848, P01584, P13073, O15239 | ATF4, IL1B, COX4I1, NDUFA1 | More | | Gliclazide | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | | Gliclazide | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Gliclazide | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Gliclazide | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Gliclazide | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | | Gliclazide | hsa05016 | Huntington disease | 4.79E-05 | 8 | O15239, P13073, Q9GZM3, P30876, P62487, P52435, P05141, Q9NYC9 | NDUFA1, COX4I1, POLR2J2, POLR2B, POLR2G, POLR2J, SLC25A5, DNAH9 | More | | Gliclazide | hsa05020 | Prion disease | 3.37E-03 | 7 | P13591, P01584, P11142, O15239, P13073, P18848, P05141 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, ATF4, SLC25A5 | More | | Gliclazide | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | | Gliclazide | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Gliclazide | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | | Gliclazide | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Gliclazide | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | | Gliclazide | hsa05140 | Leishmaniasis | 2.29E-02 | 9 | P13612, O75015, P23458, P13765, O60603, P01375, P01584, Q16539, Q15080 | ITGA4, FCGR3B, JAK1, HLA-DOB, TLR2, TNF, IL1B, MAPK14, NCF4 | More | | Gliclazide | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Gliclazide | hsa05144 | Malaria | 2.43E-04 | 8 | P60033, P69905, P68871, O60603, P01375, P35443, P01584, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Gliclazide | hsa05146 | Amoebiasis | 4.22E-03 | 11 | P01584, P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P08311 | IL1B, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, CTSG | More | | Gliclazide | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | | Gliclazide | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | | Gliclazide | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | | Gliclazide | hsa05202 | Transcriptional misregulation in cancer | 3.04E-04 | 19 | Q15532, P41732, P17844, P14780, P27930, P14923, Q16548, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | SS18, TSPAN7, DDX5, MMP9, IL1R2, JUP, BCL2A1, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Gliclazide | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Gliclazide | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | Gliclazide | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Gliclazide | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Gliclazide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.10E-02 | 8 | O95267, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539 | RASGRP1, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14 | More | | Gliclazide | hsa05321 | Inflammatory bowel disease | 7.47E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Gliclazide | hsa05332 | Graft-versus-host disease | 8.79E-03 | 3 | P01375, P26715, Q13241 | TNF, KLRC1, KLRD1 | More | | Gliclazide | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Gliclazide | hsa05415 | Diabetic cardiomyopathy | 2.87E-02 | 4 | P05141, O15239, P13073, Q13557 | SLC25A5, NDUFA1, COX4I1, CAMK2D | More | | |